4SC AG has secured funding for the further clinical development of its histone-deacetylase (HDAC) inhibitor resminostat enabling it to take the compound through a Phase 2 and pre-registration trial in patients with cutaneous T cell lymphoma (CTCL). ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
